Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)


NCTID NCT04517149 (View at clinicaltrials.gov)
Description
Development Status Inactive
Indication X-Linked Retinitis Pigmentosa
Disease Ontology Term DOID:0110414
Compound Name 4D-125
Sponsor 4D Molecular Therapeutics
Funder Type Industry
Recruitment Status
Active not recruiting
Enrollment Count 21
Results Posted Not Available

Therapy Information


Target Gene/Variant RPGR
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Intravitreal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV
Editor Type none
Dose 1 3E11 vg/eye
Dose 2 1E12 vg/eye
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2020-08-14
Completion Date 2029-05
Last Update 2025-03-21

Participation Criteria


Eligible Age >=12 Years
Standard Ages Child, Adult, Older adult
Sexes Eligible for Study MALE

Locations


No.of Trial Sites 8
Locations United States

Regulatory Information


Has US IND True
FDA Designations Fast Track, Orphan Drug Designation
Recent Updates January 2025: Sponsor announced they would terminate development of this program

Resources/Links